Skip to Content

Join the 'von Willebrand's Disease' group to help and get support from people like you.

von Willebrand's Disease News

Is Blood Donated by Mothers Less Safe for Men?

Posted 17 Oct 2017 by Drugs.com

TUESDAY, Oct. 17, 2017 – Men who receive blood donated by previously pregnant women may face an increased risk of death following the transfusion, a new study from the Netherlands suggests. Males transfused with blood from a woman with a history of pregnancy appear to be 13 percent overall more likely to die in coming years, compared with those who received blood from another man, said researchers from Sanquin, the Dutch national blood bank. The highest risk seemed to be in men 18 to 50 years old. They had a 50 percent increased risk of death after receiving blood from a previously pregnant female, said Sanquin spokesman Merlijn van Hasselt, who answered questions on behalf of the research team. "The risk remained increased for many years after transfusion. No such increase was observed for female recipients, or for male recipients over 50 years," van Hasselt said. Pregnancy might ... Read more

Related support groups: Blood Transfusion, von Willebrand's Disease, Coagulation Defects and Disorders, Bleeding Associated with Coagulation Defect, Hemophilia, Labor and Delivery including Augmentation, Hemophilia B, Hemophilia A, Blood Cell Transplantation

First Test to Detect Zika in Blood Donations Approved

Posted 7 Oct 2017 by Drugs.com

FRIDAY, Oct. 6, 2017 – The cobas Zika test has been approved by the U.S. Food and Drug Administration – the first approved screening test to detect the Zika virus in blood donations. The test is not designed to diagnose any particular person's Zika infection, however, the FDA said. In August 2016, the agency recommended that all U.S. states and territories screen blood for Zika, according to an FDA media release. "Screening blood donations for the Zika virus is critical to preventing infected donations from entering the U.S. blood supply," said Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research. Some blood-collection centers had already been using the cobas test in order to comply with the 2016 edict. Data collected from this testing, in tandem with additional information provided by the test's manufacturer, were used to approve the diagnostic, the FDA ... Read more

Related support groups: Blood Transfusion, Insect Bites, von Willebrand's Disease, Coagulation Defects and Disorders, Hemophilia, Zika Virus Infection, Blood Cell Transplantation

Health Tip: Giving Blood

Posted 4 Oct 2017 by Drugs.com

-- Donating blood for the first time may sound intimidating. But the process is fairly painless, takes only about 20 minutes and could help save a life. The American Red Cross explains the different types of blood donation: Whole blood – The most common and quickest type of donation, involving a pint of whole blood. The donation is typically separated into transfusable components, including red cells, plasma and platelets. Red cells – Red blood cells are the most frequently transfused part of blood. In this type of collection, only the red blood cells are collected and most of the platelets and plasma are returned to the donor. Platelet – Platelet donations take longer than whole-blood donations. During this procedure, an apheresis machine collects platelets and returns red cells and the majority of the plasma back to the donor. Platelets are an important part of some cancer ... Read more

Related support groups: Blood Disorders, Bleeding Disorder, Anemia, Blood Transfusion, von Willebrand's Disease, Hemophilia, Anemia Associated with Chronic Disease, Blood Cell Transplantation

Vonvendi Approved to Control Bleeding Disorder

Posted 12 Dec 2015 by Drugs.com

TUESDAY, Dec. 8, 2015 – Vonvendi has been approved to treat adults with von Willebrand disease (VWD), the most common inherited bleeding disorder. VWD, affecting about 1 percent of the U.S. population, is caused by lack of a protein that's essential for blood clotting. People with the disorder can develop severe bleeding from the nose, gums, intestines, muscles and joints. Women with VWD also can bleed excessively after a menstrual period or after giving birth. Vonvendi, a genetically engineered (recombinant) form of the missing protein, was evaluated in clinical studies of 69 adults with VWD. Itching was the most common side effect, the FDA said Tuesday in a news release. Vonvendi is produced by Baxalta, based in Westlake Village, Calif. More information Visit the FDA to learn more. Read more

Related support groups: von Willebrand's Disease, Vonvendi, Von Willebrand Factor (recombinant)

FDA Approves Vonvendi (Von Willebrand Factor (Recombinant)) to Treat Bleeding Episodes in Patients with VWD

Posted 10 Dec 2015 by Drugs.com

December 8, 2015 – The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed with VWD. VWD is the most common inherited bleeding disorder, affecting approximately 1 percent of the U.S. population. Men and women are equally affected by VWD, which is caused by a deficiency or defect in von Willebrand factor, a protein that is critical for normal blood clotting. Patients with VWD can develop severe bleeding from the nose, gums, and intestines, as well as into muscles and joints. Women with VWD may have heavy menstrual periods lasting longer than average and may experience excessive ... Read more

Related support groups: von Willebrand's Disease, Von Willebrand Factor, Vonvendi, Von Willebrand Factor (recombinant)

Octapharma USA Announces FDA Approval of Wilate - the First Replacement Therapy Developed Specifically for von Willebrand Disease

Posted 9 Dec 2009 by Drugs.com

HOBOKEN, N.J., Dec. 7 /PRNewswire/ – Octapharma USA today announced the U.S. Food and Drug Administration has approved wilate for the treatment of spontaneous and trauma-induced bleeding episodes in patients with all types of von Willebrand disease (VWD). Wilate is a newly developed, high-purity, double virus inactivated von Willebrand Factor/Coagulation Factor VIII Concentrate (Human) that demonstrated efficacy for all types of VWD, including pediatric patients, in four prospective clinical trials utilizing both objective and subjective criteria. Wilate is indicated for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe VWD as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.(1) Wilate is the first double virus inactivated VWF/FVIII (von Willebrand Factor / ... Read more

Related support groups: von Willebrand's Disease

Ask a Question

Further Information

Related Condition Support Groups

Coagulation Defects and Disorders

Related Drug Support Groups

desmopressin, DDAVP, von willebrand factor, Humate-P, Stimate, antihemophilic factor / von willebrand factor, Wilstart, Haemate P, Optivate, Alphanate, Wilfactin, Wilate, Vonvendi